A Multiantigen Vaccine Targeting EMT-Associated Proteins to Prevent Recurrent Ovarian Cancer
Abstract
Our hypothesis is that OVAC4, a multi-antigen, multi-epitope vaccine targeting immunogenic proteins associated with mesenchymal transition (EMT), could be an effective method to prevent the development of EMT and ovarian cancer relapse. The specific aims are to (1) determine whether vaccination with OVAC4, concurrent with cisplatin therapy, can prevent the upregulation of EMT associated proteins in the tumor, (2) evaluate the tumor response rate and overall survival of mice treated with OVAC4 and cisplatin with or without an anti-PD-1 monoclonal antibody, and (3) assess any potential short or long-term toxicity of immunization with OVAC4. Our approach focuses on determining the mechanisms by which OVAC4 induces an anti-tumor response and inhibits the development of metastases. The data generated in this proposal will serve as the basis for an Investigational New Drug (IND) application to the FDA for the human translation of OVAC4.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 01, 2023
- Accession Number
- AD1214132
Entities
People
- Mary L. Disis
Organizations
- University of Washington